Neoadjuvant Therapy for HR+ Breast Cancer
Dr Kevin Kalinsky describes when and for whom neoadjuvant therapy may be appropriate for the management of HR-positive breast cancer.
EP: 1.Optimizing Systemic Therapy for Early-Stage HR+ Breast Cancer
EP: 2.Perioperative Decision-Making in HR+ Breast Cancer
EP: 3.Role of Gene Profiling Assays in Early-Stage HR+ Breast Cancer
EP: 4.The Oncotype DX Breast Recurrence Score: Clinical Trial Data
EP: 5.Gene Profile-Directed Therapy for Early-Stage HR+ Breast Cancer
EP: 6.NCCN Guidance on Gene Profiling in Early-Stage HR+ Breast Cancer
EP: 7.Informed Decision-Making in HR+ Breast Cancer
Now Viewing
EP: 8.Neoadjuvant Therapy for HR+ Breast Cancer
EP: 9.Genomic Assays and Adjuvant Therapy for HR+ Breast Cancer
EP: 10.Genomic Testing vs Genetic Testing for HR+ Breast Cancer
EP: 11.The Oncotype DX Breast Recurrence Score for HR+ Breast Cancer
Related Videos
Related Content
Treatment Options in Metastatic Castration-Sensitive Prostate Cancer
March 13th 2022Article
In this program Atish D. Choudhury, MD, PhD, discusses recent updates on long-term safety and efficacy data in patients with metastatic castration-sensitive prostate cancer and the importance of patient communication and quality of life while on treatment.
